Quantcast
Channel: Endpoints News
Viewing all articles
Browse latest Browse all 3654

After hunt for alternatives, Kronos Bio selects Tang Capital's Concentra for a deal

$
0
0
Kronos Bio, the drug developer long led by Gilead veteran Norbert Bischofberger, is calling it quits. The biotech said Thursday it's selling to Tang Capital's shell company Concentra Biosciences for 57 ...

Viewing all articles
Browse latest Browse all 3654